Hims & Hers: Strong Growth Meets Insider Selling Activity

The telehealth platform Hims & Hers Health is presenting a compelling case study in contrasts. While the company's latest financial results showcase a business in hyper-growth mode, a concurrent announcement of stock sales by a senior executive introduces a note of caution for investors. This combination of robust fundamentals and insider divestment creates a complex narrative for the market to decipher.

Hims & Hers reported exceptionally strong results for the third quarter of 2025. Revenue surged by an impressive 49% year-over-year, reaching nearly $600 million. Perhaps even more significant was the bottom-line performance: the company recorded a net profit of approximately $16 million, demonstrating that rapid expansion does not have to come at the expense of profitability.

The subscriber base grew to just under 2.5 million, marking a 21% increase over the past twelve months. With an adjusted EBITDA exceeding $78 million, the company continues to validate its business model and prove its capacity for scaling operations effectively.

Upward Revision of Full-Year Outlook

Bolstered by this powerful performance, the company's leadership has raised its financial guidance for the full fiscal year 2025. The projected revenue range is now narrowed to $2.335 billion to $2.355 billion, representing a significant improvement over prior forecasts. Management also increased its expectations for adjusted EBITDA, now anticipating between $307 million and $317 million.

The outlook for the current fourth quarter remains equally optimistic, with the company providing the following projections:
* Revenue forecast: $605 million to $625 million
* Estimated adjusted EBITDA: $55 million to $65 million

Should investors sell immediately? Or is it worth buying Hims & Hers?

These upward revisions reinforce the company's sustained growth trajectory and suggest continued operational momentum.

Executive Stock Sale: Context and Questions

Amid these positive developments, a filing on November 10, 2025, revealed that Soleil Boughton, a senior executive at Hims & Hers, plans to divest 2,637 shares. Although this transaction is scheduled under a pre-arranged trading plan—a common practice for corporate insiders—the timing inevitably raises questions.

The stock currently trades approximately 46% below its 52-week high of 66 euros, despite the company's strong underlying financial health. This divergence prompts investors to consider whether the executive's move signals an anticipated consolidation phase or simply represents a routine personal financial decision.

The juxtaposition of outstanding quarterly results and insider selling creates a dynamic tension. While the fundamental business metrics appear overwhelmingly positive, the planned divestment by a company leader introduces an element of ambiguity into the market's assessment. The central question for shareholders is whether the stock will maintain its growth trajectory or if a period of adjustment lies ahead.